Literature DB >> 29762749

Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis.

Iain D Page1,2, Malcolm D Richardson1,2,3, David W Denning1,2.   

Abstract

Chronic pulmonary aspergillosis (CPA) complicates underlying lung disease, including treated tuberculosis. Measurement of Aspergillus-specific immunoglobulin G (IgG) is a key diagnostic step. Cutoffs have been proposed based on receiver operating characteristic (ROC) curve analyses comparing CPA cases to healthy controls, but performance in at-risk populations with underlying lung disease is unclear. We evaluated optimal cutoffs for the Siemens Immulite Aspergillus-specific IgG assay for CPA diagnosis in relation to large groups of healthy and diseased controls with treated pulmonary tuberculosis. Sera from 241 patients with CPA attending the UK National Aspergillosis Centre, 299 Ugandan blood donors (healthy controls), and 398 Ugandans with treated pulmonary tuberculosis (diseased controls) were tested. Radiological screening removed potential CPA cases from diseased controls (234 screened diseased controls). ROC curve analyses were performed and optimal cutoffs identified by Youden J statistic. CPA versus control ROC area under curve (AUC) results were: healthy controls 0.984 (95% confidence interval 0.972-0.997), diseased controls 0.972 (0.959-0.985), screened diseased controls 0.979 (0.967-0.992). Optimal cutoffs were: healthy controls 15 mg/l (94.6% sensitivity, 98% specificity), unscreened diseased controls 15 mg/l (94.6% sensitivity, 94.5% specificity), screened diseased controls 25 mg/l (92.9% sensitivity, 98.7% specificity). Results were similar in healthy and diseased controls. We advocate a cutoff of 20 mg/l as this is the midpoint of the range of optimal cutoffs. Cutoffs calculated in relation to healthy controls for other assays are likely to remain valid for use in a treated tuberculosis population.
© The Author(s) 2018. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Entities:  

Keywords:  zzm321990 Aspergillus fumigatuszzm321990 ; CPA; aspergilloma; aspergillosis; immulite 2000

Mesh:

Substances:

Year:  2019        PMID: 29762749     DOI: 10.1093/mmy/myy024

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  5 in total

1.  Accuracy of serological tests for diagnosis of chronic pulmonary aspergillosis: A systematic review and meta-analysis.

Authors:  Cláudia Elizabeth Volpe Chaves; Sandra Maria do Valle Leone de Oliveira; James Venturini; Antonio Jose Grande; Tatiane Fernanda Sylvestre; Rinaldo Poncio Mendes; Anamaria Mello Miranda Paniago
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

2.  Standardization of Aspergillus IgG diagnostic cutoff in Nigerians.

Authors:  Rita O Oladele; Akaninyene A Otu; Oluwaseyi J Balogun; Oladayo M Babalola; Augustina O Nwosu; Iriagbonse Iyabo Osaigbovo; Titilayo Gbajabiamila; Nicholas K Irurhe; Samuel A Fayemiwo; Shuwaram A Shettima; Nkolika Stella Uwaezuoke; Chinagozi Precious Edwin; Toyese Stephen Ayanbeku; Joy U Okaa; Charles John Elikwu; David W Denning; Phyllis J Kanki; Folasade T Ogunsola
Journal:  Ther Adv Infect Dis       Date:  2021-10-09

Review 3.  Role of Serological Tests in the Diagnosis of Mold Infections.

Authors:  Malcolm Richardson; Iain Page
Journal:  Curr Fungal Infect Rep       Date:  2018-09-05

4.  Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.

Authors:  Iain D Page; Rosemary Byanyima; Sharath Hosmane; Nathan Onyachi; Cyprian Opira; Malcolm Richardson; Richard Sawyer; Anna Sharman; David W Denning
Journal:  Eur Respir J       Date:  2019-03-18       Impact factor: 16.671

5.  Potential value of serum Aspergillus IgG antibody detection in the diagnosis of invasive and chronic pulmonary aspergillosis in non-agranulocytic patients.

Authors:  Qihong Yu; Jingdong He; Bin Xing; Xin Li; Hongyu Qian; Hong Zhang; Meilin Xu; Haiying Peng
Journal:  BMC Pulm Med       Date:  2020-04-15       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.